Mauna Kea Technologies, Inc., a leader in the in vivo cellular imaging market, announced that Cellvizio probe-based confocal laser endomicroscopy will be featured in key presentations at the annual Digestive Disease Week (DDW) 2010 conference taking place in New Orleans May 1st thru the 5th. DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
"Data presented at this year's DDW significantly validate Cellvizio as a vital tool to improve early detection of GI and biliary cancers," said Sacha Loiseau, President and Chief Executive Officer of Mauna Kea Technologies. "Clinical evidence continues to show that the cellular-level information that this new imaging tool provides is helping physicians more effectively evaluate their patients conditions and make decisions on which surveillance or treatment option to consider."
Highlights include the results of "DONT BIOPCE study" (Oral Presentation #1071), the large, prospective multi-center, international, randomized, controlled trial designed to evaluate if Cellvizio could improve outcomes and surveillance efficiency in patients with Barrett's esophagus, as well as the findings from the large, multi-center Cellvizio ERCP registry trial (Oral Presentation #788) for the evaluation of indeterminate strictures the bile and pancreatic ducts.
AI-powered ECG model predicts heart disease risk with precision